Kawashima Y, Serigano T, Hino T, Yamamoto H, Takeuchi H
Gifu Pharmaceutical University, Japan.
Pharm Res. 1998 Nov;15(11):1748-52. doi: 10.1023/a:1011916930655.
A new particle design method to improve the aerosolization properties of a dry powder inhalation system was developed using surface modification of hydrophobic drug powders (pranlukast hydrate) with ultrafine hydrophilic particles, hydroxypropylmethylcellulose phthalate (HPMCP) nanospheres. The mechanism of the improved inhalation properties of the surface-modified particles and their deposits on carrier particles (lactose) was clarified in vitro.
Drug particles were introduced to aqueous colloidal HPMCP dispersions prepared by emulsion-solvent diffusion techniques followed by freeze- or spray-drying of the resultant aqueous dispersions. The surface-modified powders obtained with HPMCP nanospheres and their mixture with lactose powders were aerosolized by Spinhaler and their mode of deposition in lung was evaluated in vitro using a twin impinger. To elucidate the inhalation mechanism of these surface modified particles, we measured their modified micromeritic properties, such as surface topography, specific surface area, dissolution rate, and dispersibility in air.
Dramatically improved inhalation properties of the surface modified powder, i.e. a two-fold increase in emission and a three-fold increase in delivery to deep lung, were found in vitro compared with the original unmodified powder. Improved inhalation was also found with the surface-modified drug deposited on lactose particles. Those improvements were attributed to the increased surface roughness and hydrophilicity of the surface-modified particles, and the resultant increased dispersibility in air.
Surface modification of hydrophobic drug particles with HPMCP nanospheres to improve hydrophilicity was extremely useful in increasing the inhalation efficiency of the drug itself and the drug deposited on carrier; this was attributed to increased dispersibility in air and emission from the device, for spray- and freeze-dried particles, respectively.
开发一种新的颗粒设计方法,通过用超细亲水性颗粒羟丙基甲基纤维素邻苯二甲酸酯(HPMCP)纳米球对疏水性药物粉末(水合普仑司特)进行表面改性,来改善干粉吸入系统的雾化性能。在体外阐明了表面改性颗粒吸入性能改善的机制及其在载体颗粒(乳糖)上的沉积情况。
将药物颗粒引入通过乳液 - 溶剂扩散技术制备的HPMCP水性胶体分散体中,然后将所得的水性分散体进行冷冻干燥或喷雾干燥。用HPMCP纳米球获得的表面改性粉末及其与乳糖粉末的混合物通过Spinhaler雾化,并使用双级冲击器在体外评估它们在肺部的沉积模式。为了阐明这些表面改性颗粒的吸入机制,我们测量了它们改性后的粉体学性质,如表面形貌、比表面积、溶解速率和在空气中的分散性。
与原始未改性粉末相比,在体外发现表面改性粉末的吸入性能有显著改善,即排放量增加了两倍,向深部肺部的递送量增加了三倍。在沉积于乳糖颗粒上的表面改性药物中也发现了吸入性能的改善。这些改善归因于表面改性颗粒表面粗糙度和亲水性的增加,以及由此导致的在空气中分散性的增加。
用HPMCP纳米球对疏水性药物颗粒进行表面改性以提高亲水性,对于提高药物本身以及沉积在载体上的药物的吸入效率极为有用;这分别归因于喷雾干燥和冷冻干燥颗粒在空气中分散性的增加以及从装置中的排放量增加。